BIOIMPRESIÓN 3D

VolverVolver

Resultados 167 resultados LastUpdate Última actualización 03/10/2022 [13:16:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



previousPage Página2 de 7 nextPage   por página


一种藤黄酸纳米制剂及其制备方法

NºPublicación: CN115093434A 23/09/2022

Solicitante:

中国中医科学院中药研究所

Resumen de: CN115093434A

本发明提供了一种藤黄酸纳米制剂及其制备方法,属于制药领域。本发明构建了一种肝癌细胞靶向的还原敏感载体GA‑PEG2k‑SS‑PCL5k用于藤黄酸二聚体前药的有效递送,使藤黄酸二聚体前药结构更容易被药物载体通过疏水相互作用包裹进入内核。该药物载体GA‑PEG2k‑SS‑PCL5k与藤黄酸二聚体能够形成稳定的GA‑PEG2k‑SS‑PCL5k/藤黄酸二聚体纳米制剂,该纳米制剂的包封率高达95.97%,载药量高达30.45%,应用前景广阔。

traducir

一种烷基葡糖酰胺与IR780复合的选择性光热杀菌纳米材料及其制备方法和应用

NºPublicación: CN115089706A 23/09/2022

Solicitante:

华南农业大学

Resumen de: CN115089706A

本发明公开了一种烷基葡糖酰胺与IR780复合的选择性光热杀菌纳米材料及其制备方法和应用。所述选择性光热杀菌纳米材料由烷基葡糖酰胺、荧光染料IR780和助表面活性剂作为原料制备获得,所述选择性光热杀菌纳米材料为核壳结构,外壳为烷基葡糖酰胺,内核为荧光染料IR780。所述选择性光热杀菌纳米材料载药率高,稳定性好,且粒径小,粒径均匀性好;其包封率可达95%,载药率可接近4.5%,且制备成功后24小时内无IR780的析出,光吸收谱稳定。此外,该纳米材料具有选择性杀灭作用,杀菌效率高,可在5min内升温达20摄氏度,实现快速杀菌作用,且毒性小,具有较好的生物安全性。

traducir

一种基于微流控芯片的载药聚多巴胺铁纳米颗粒的制备方法及其应用

NºPublicación: CN115089560A 23/09/2022

Solicitante:

东华大学

Resumen de: CN115089560A

本发明涉及一种基于微流控芯片的载药聚多巴胺铁纳米颗粒的制备方法及其应用,所述纳米颗粒以含二价铁离子、多巴胺、药物、蛋白的原料,通过微流控芯片获得。本发明以微流控芯片为反应器制备的纤连蛋白包覆的载药聚多巴胺铁纳米颗粒,生物安全性好,可特异性靶向肿瘤区域,选择性递送药物,实现T1磁共振成像,同时实现肿瘤的增强化学动力治疗/化疗/免疫治疗三模态联合治疗,在癌症诊疗方面具有潜在的应用前景。

traducir

一种细胞膜包被的前药纳米粒、制备方法及应用

NºPublicación: CN115089561A 23/09/2022

Solicitante:

浙江大学医学院附属第一医院

Resumen de: CN115089561A

本发明公开了一种细胞膜包被的前药纳米粒,包括:由脂质单分子层和装载于所述脂质单分子层中的SN38前药组成的SN38前药脂质纳米粒以及包裹在纳米粒外面的细胞膜;所述的脂质单分子层由卵磷脂、胆固醇和DDAB/DOTAP作为骨架,同时以DSPE‑PEG2k双亲性聚合物作为添加剂。本发明同时提供了一种上述细胞膜包被的前药纳米粒的制备方法及应用。本发明的这种仿生纳米载药平台表现出活性药物的酯酶响应性释放,显著延长了药物的体内循环时间,提高了药物的生物利用度,增强了药物的抗肿瘤生长的效果。本发明提供的仿生纳米载药平台为小分子化疗药物提供了广阔的临床转化前景,也为肿瘤治疗提供的新的选择方案。

traducir

METHODS OF CANCER TREATMENT BY DELIVERY OF SIRNAS AGAINST BCLXL AND MCL1 USING A POLYPEPTIDE NANOPARTICLE.

NºPublicación: WO2022197607A2 22/09/2022

Solicitante:

SIRNAOMICS INC [US]

US_2022288228_PA

Resumen de: WO2022197607A2

Compositions and methods are provided for the silencing of the BCLxL and MCL1 genes. Specifically, siRNA compositions are provided that contain siRNA molecules that target the BCLxL and MCL1 genes. Methods for using these compositions for treating cancer also are provided.

traducir

PD-L1 AND TLR7 DOUBLE-TARGETING NANOBODY COUPLING DRUG AND USE THEREOF IN ANTI-TUMOR

NºPublicación: WO2022194153A1 22/09/2022

Solicitante:

SHANGHAI INST MATERIA MEDICA CAS [CN]

CN_115068625_A

Resumen de: WO2022194153A1

Disclosed in the present invention are a use of a combination of an anti-PD-L1 nanobody and a TLR7 small molecule agonist in anti-tumor treatment, and a PD-L1 and TLR7 double-targeting nanobody coupling drug, a preparation method therefor, and a use thereof. Specifically, disclosed in the present invention are a use and solution of a combination of an anti-PD-L1 nanobody and a derived protein thereof as well as a TLR7 small molecule agonist and a derived compound thereof in anti-tumor treatment. Meanwhile, disclosed in the present invention are design, preparation, and identification solutions for a novel PD-L1 and TLR7 double-targeting nanobody drug conjugate and a derived molecule thereof, and an effect of the novel PD-L1 and TLR7 double-targeting nanobody drug conjugate in anti-tumor treatment. The PD-L1 and TLR7 double-targeting nanobody drug conjugate of the present invention can yield a significant antineoplastic efficacy in various transplantation tumor models.

traducir

EXTRACELLULAR VESICLE-BASED NANOCARRIERS

NºPublicación: WO2022198187A1 22/09/2022

Solicitante:

OHIO STATE INNOVATION FOUNDATION [US]

Resumen de: WO2022198187A1

Disclosed herein is a system that engages skin-resident APCs by directly delivering a vaccine composition, and a system that turns skin cells into a vaccine dispatch center to amplify immunity via the production of engineered extracellular vesicles (EVs) functionalized with targeting ligands and loaded with the vaccine composition that can be targeted to extracutaneous APCs. In particular, disclosed herein is a vaccine composition that involves a first polynucleotide encoding or comprising a viral, bacterial, or tumor antigen, and a second polynucleotide encoding a fusion protein comprising an APC-targeting ligand and an exosomal or lysosomal transmembrane protein. Also disclosed is a method of vaccinating a subject that involves transfecting skin cells of the subject with the disclosed vaccine composition. Also disclosed herein is a method of vaccinating a subject that involves administering to the subject the disclosed EV vaccine.

traducir

POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF

NºPublicación: WO2022198099A1 22/09/2022

Solicitante:

RECODE THERAPEUTICS INC [US]

Resumen de: WO2022198099A1

Compositions of polynucleotide(s) are disclosed. A polynucleotide may encode for a polypeptide, protein, or functional fragment thereof associated with primary ciliary dyskinesia (PCD). Pharmaceutical compositions, kits, and methods for treating a disease or condition associated with cilia maintenance and function, and impaired function of the axoneme are also disclosed. The polynucleotide may be combined with a lipid composition.

traducir

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

NºPublicación: WO2022198229A1 22/09/2022

Solicitante:

UNIV NEBRASKA [US]

Resumen de: WO2022198229A1

Disclosed herein are methods and compositions for lipid nanoparticles encapsulating a nucleic acid encoding for a CRISPR nucleic acid complementary to a HIV-1 gene. Also disclosed are lipid nanoparticle compositions, nucleotides, cells, and methods associated with the compositions.

traducir

LIPID-BASED NANOPARTICLE DELIVERY SYSTEM FOR HYDROPHILIC CHARGED COMPOUND

NºPublicación: WO2022197988A1 22/09/2022

Solicitante:

UNIV NAT TAIWAN

WO_2022197989_PA

Resumen de: WO2022197988A1

A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API) complexes, wherein each lipid- API complex comprises a complex of anionic lipid and API wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention.

traducir

A STABLE OPHTHALMIC NANOSUPENSION OF BRINZOLAMIDE

NºPublicación: WO2022195382A1 22/09/2022

Solicitante:

INDOCO REMEDIES LTD [IN]

Resumen de: WO2022195382A1

The present invention relates to a stable ophthalmic nanosuspension of brinzolamide and a method of preparing same, which is chemically stable at room temperature and free of quaternary ammonium salt. Moreover, the composition of present invention is sterile aqueous ophthalmic nanosuspension.

traducir

COMPOSITION AND METHOD OF PREPARATION FOR LIPID FORMULATIONS COMPRISING CHARGED LIPIDS

NºPublicación: WO2022197989A1 22/09/2022

Solicitante:

FORMURX PHARMACEUTICALS CO LTD

WO_2022197988_PA

Resumen de: WO2022197989A1

A lipid-based nanoparticle (LNP) with high DL ratio and normalized release. The LNP of the present invention comprises an outer lipid monolayer encapsulating a plurality of lipid-active pharmaceutical ingredient (API)-ion complexes, wherein each lipid- API-ion complex comprises a complex of anionic lipid, API and ion wherein the API comprises a positively charged form of an API and wherein the outer lipid monolayer of the LNP comprises neutral lipids. The present invention further comprises a method of preparation of the LNP of the present invention.

traducir

DENDRITIC PEPTIDE CONJUGATED POLYMERS FOR EFFICIENT INTRACELLULAR DELIVERY OF NUCLEIC ACIDS TO IMMUNE CELLS

NºPublicación: WO2022197977A1 22/09/2022

Solicitante:

UNIV NORTHWESTERN [US]

Resumen de: WO2022197977A1

The present invention provides nanocarriers for delivering polynucleotide sequences to cells, specifically immune cells, including dendritic cells and methods of use. The methods provide improved delivery and reduced toxicity over prior methods. The method of the present disclosure provide a system for delivering nucleic acids to a cell, consisting of a synthetic PEG-b-PPS-linker-DP polymer for producing nanostructures comprising a poly(ethylene glycol)-blockpoly(propylene sulfide) copolymer (PEG-b-PPS) conjugated with a dendritic-specific branched cationic peptide (DP). The system provides a non-toxic in-vitro method of delivering a polynucleotide to immune cells, including dendritic cells, comprising of contacting the cell in cell culture medium with a nanocarrier wherein the method is non-toxic to the cells. The methods described in the invention can be used for treating a subject in need of gene therapy, comprising administering to the subject an effective amount of the system comprising of a polynucleotide, wherein the polynucleotide contains a gen of interest for gene therapy.

traducir

A METHOD FOR OBTAINING ION-EXCHANGE POLYMERIC HYDROGELS FOR EYE TREATMENT AND HYDROGEL LENSES THEREOF

NºPublicación: US2022296506A1 22/09/2022

Solicitante:

SIA MEDHYDROGEL [LV]

Resumen de: US2022296506A1

The present invention could be used in medicine and relates to a method of producing ion-exchange polymeric hydrogels for eye treatment, which includes monomer copolymerization under ionizing radiation in presence of linking agent and ionites, when copolymerization is carried out gradually to obtain a prepolymer of desired viscosity for filling lens forms, and ionites introduction in the form of finely dispersed powder, filing the hydrogel into lens forms and subsequent copolymerization till an adequate ionizing dosage is performed providing a gel suitable for lenses formation, characterized in that the gel is also filled with pharmaceutically active agent in the form of finely dispersed powder prior to ionite introduction, and the size of particles of PAA is lower that the size of ionite particles. The present invention also relates to therapeutic hydrogel lenses produced in accordance with the above-mentioned method.

traducir

Dendrimer delivery system and methods of use thereof

NºPublicación: AU2022221454A1 22/09/2022

Solicitante:

UNIV JOHNS HOPKINS [US]

JP_2021502451_A

Resumen de: AU2022221454A1

DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. -120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.

traducir

Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof

NºPublicación: AU2021231160A1 22/09/2022

Solicitante:

PROGENEER INC

WO_2021177679_A1

Resumen de: AU2021231160A1

The present invention relates to: a lyophilized preparation of a pathogen cell wall skeleton, the preparation containing the pathogen cell wall skeleton as an active ingredient; various live-pathogen-mimetic nanoparticles produced by using the lyophilized preparation and antagonists of toll-like receptor 7 or 8 which can induce the efficacy of the live pathogen; a use thereof; and a production method thereof.

traducir

Methods and compositions using synthetic nanocarriers comprising immunosuppressant

NºPublicación: AU2021225955A1 22/09/2022

Solicitante:

SELECTA BIOSCIENCES INC

US_2021290601_A1

Resumen de: AU2021225955A1

Provided herein are methods and compositions related to synthetic nanocarriers comprising an immunosuppressant that can be used, for example, for inducing autophagy and/or promoting a tolerogenic phenotype.

traducir

Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells

NºPublicación: AU2021218409A1 22/09/2022

Solicitante:

GENEVANT SCIENCES GMBH

WO_2021163339_A1

Resumen de: AU2021218409A1

Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.

traducir

Methods of preparing lipid nanoparticles

NºPublicación: AU2021212262A1 22/09/2022

Solicitante:

MODERNATX INC

TW_202139976_A

Resumen de: AU2021212262A1

The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.

traducir

METHODS AND COMPOSITIONS FOR PREVENTING SKIN TOXICITIES CAUSED BY BIOLOGICAL TARGETED CANCER DRUGS

NºPublicación: US2022296543A1 22/09/2022

Solicitante:

HADASIT MEDICAL RES SERVICES & DEVELOPMENT LIMITED [IL]
YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD [IL]

WO_2021028919_A1

Resumen de: US2022296543A1

Provided are methods for inhibiting binding of systemically administered drugs to a target in the skin by topically administering materials prior to or concomitantly with administration of the systemic drugs.

traducir

NANOEMULSION OF 18BETA-GLYCYRRHETINIC ACID

NºPublicación: US2022296544A1 22/09/2022

Solicitante:

ATSO CORP AFFAIRS S A DE C V [MX]

BR_112022002176_A2

Resumen de: US2022296544A1

The invention refers to pharmaceutical forms that potentiate the bioavailability of 18β-GA, having a high permeation on the application area mainly due to the effect of their small particle size, high concentration of the active ingredient, excipient composition, micelles with specific structural composition and polarity. The present pharmaceutical forms exhibit specific values for particle size, permeability, diffusion coefficient, and polydispersity helping to provide its technical advantages. Therapeutic uses of the pharmaceutical forms are also described, which include those therapeutic uses for which 18β-glycyrrhetinic acid is known to have an effect, such as anti-inflammatory, antiviral, antibacterial activity, hepatoprotective, used against skin diseases and anticarcinogenic. Mainly gelled solutions, emulsions and nanoemulsions, are intended for application in the vaginal and cervical area, for the treatment of diseases related to the human papillomavirus, such as infections, lesions, and cervical cancer.

traducir

PHARMACEUTICAL COMPOSITIONS

NºPublicación: US2022296575A1 22/09/2022

Solicitante:

XSPRAY PHARMA AB [SE]

US_2022168285_A1

Resumen de: US2022296575A1

The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.

traducir

Small Molecule Agents, Compositions, and Formulations, for Internal Use, Displaying Inhibitory Activity Against Gram-positive and/or Gram-negative Organisms

NºPublicación: US2022296549A1 22/09/2022

Solicitante:

NATUREZA INC [US]

CA_3072197_A1

Resumen de: US2022296549A1

Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species.

traducir

NANOEMULSION WITH PORPHYRIN SHELL

NºPublicación: US2022296731A1 22/09/2022

Solicitante:

UNIV HEALTH NETWORK [CA]

CN_114222591_PA

Resumen de: US2022296731A1

There is described herein a nanoparticle comprising an outer shell comprising a porphyrin salt, an expanded porphyrin salt or an analog of porphyrin salt, around an inner oil core.

traducir

ROOM TEMPERATURE STABLE, SINGLE SHOT mRNA VACCINE FOR COVID-19

Nº publicación: US2022296728A1 22/09/2022

Solicitante:

CASTOR TREVOR PERCIVAL [US]

Resumen de: US2022296728A1

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

traducir

previousPage Página2 de 7 nextPage por página

punteroimgVolver